Here are the 424B prospectus supplements from Portage Biotech Inc. (PRTG) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PRTG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRTG filings page.
AlphaTON Capital Corp is launching an at-the-market equity program to sell up to $400,000,000 of ordinary shares through H.C. Wainwright as sales agent or principal. Shares may be sold from time to time on Nasdaq under the symbol ATON or through other permitted methods at prevailing market prices.
The company plans to use net proceeds mainly to fund capital expenditures for Cocoon AI, including servers, GPUs and related infrastructure, and to pursue strategic acquisitions or investments aligned with the Telegram and TON ecosystem, with any remainder for working capital and general corporate purposes.
As context, AlphaTON reports 23,434,588 ordinary shares outstanding as of February 13, 2026, so issuing a large portion of the program would significantly increase the share count and dilute existing holders. Wainwright will receive up to a 3.0% sales commission on gross proceeds.